ECM
NBSE

ExodusPoint Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

ExodusPoint Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-560
Closed -$98K – 2334
2020
Q2 		$98K Sell
560
-30
-5% -$5.02K ﹤0.01% 1632
2020
Q1 		$84K Sell
590
-21
-3% -$2.78K ﹤0.01% 909
2019
Q4 		$88K Buy
+611
New +$71.7K ﹤0.01% 1436

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ExodusPoint Capital Management's NBSE Position: Q3 2020 in Review

ExodusPoint Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2020, closing a stake of 560 shares — an estimated $98K sold.

ExodusPoint Capital Management first reported a position in NBSE in Q4 2019 and held it in 3 quarters. The position peaked at $98K in Q2 2020. 50 funds tracked by Wall St. Rank hold NBSE as of Q3 2020.

  • ExodusPoint Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • ExodusPoint Capital Management sold 560 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $98K.
  • ExodusPoint Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
  • ExodusPoint Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $98K in Q2 2020.
  • 50 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2020.

Based on ExodusPoint Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.